- Home
- ACON
ACON
Aclarion Inc.
as 11-18-2024 9:41am EST
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The Company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | BROOMFIELD |
| Market Cap: | 1.7M | IPO Year: | 2022 |
| Target Price: | $1.50 | AVG Volume (30 days): | 748.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.05 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.16 - $7.39 | Next Earning Date: | 11-14-2024 |
| Revenue: | $49,289 | Revenue Growth: | -41.41% |
| Revenue Growth (this year): | -1.25% | Revenue Growth (next year): | 256.16% |
Latest Aclarion Inc. News
ACON Breaking Stock News: Dive into ACON Ticker-Specific Updates for Smart Investing
ACCESSWIRE
4 days ago
Aclarion to Present at the Virtual Investor Summit Microcap Event on November 21st
GlobeNewswire
a month ago
Aclarion to Participate in the 2024 Maxim Healthcare Virtual Summit
GlobeNewswire
2 months ago
Aclarion's Nociscan AI Plays Key Role in Advanced Understanding of Modic Changes
MT Newswires
2 months ago
Aclarion Establishes $10 Million At-The-Market Offering Program
GlobeNewswire
2 months ago
PRISM MarketView Showcases Aclarion: Disrupting Chronic Pain Treatment with Nociscan AI Technology
GlobeNewswire
2 months ago
Aclarion Provides Corporate Update on Nociscan AI Technology Milestones
ACCESSWIRE
2 months ago
Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing
GlobeNewswire
2 months ago
Aclarion Announces Completion of First Nociscan Exams in LIFEHAB Trial
Compare ACON vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ACON Aclarion Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.